PMI Increasing Global Response To Counterfeit Antimalarial Drugs

In an update from the President’s Malaria Initiative (PMI), U.S. Global Malaria Coordinator Rear Adm. Tim Ziemer said PMI “is greatly concerned by the scourge of counterfeit and substandard drugs, and is increasing its financial and programmatic support to technical and regulatory capacities in partner countries. PMI is also urging greater international cooperation on the issue.” The statement continues, “PMI is committed to ensuring that all persons with malaria are promptly diagnosed and treated with a safe and efficacious antimalarial drug. PMI takes all reports of suspect counterfeits and illegal diversion seriously.” The update notes the publication this week of a Wall Street Journal investigation into counterfeit and substandard malaria drugs, and describes multiple ways PMI “is responding to this threat.” The update continues, “Despite these challenges, the unprecedented scale-up of malaria prevention and treatment interventions over the past 10 years in sub-Saharan Africa is having a major impact on malaria illnesses and deaths” and “PMI continues to see strong progress” (5/30).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.